Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (13436)	4/26/2004 7:20:31 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

With so many investments to choose from, many with honest management and long term records of steady growth, why would anyone want to buy or hold a stock when the only thing going for it is "mysterious buying" ? It's the triumph of hope over experience. Money has been flooding into the biotech market. Every bio that I follow has at least doubled in the last 12 months and many are up far more. Take a look at the Nasdaq or Amex biotech index. Meantime DMX keeps sinking. Today alone, the bio indexes were up 3% and DMX keeps sinking. With all the money flooding into the sector, its not surprising that some of it would go into the crappiest stocks as some people inevitably go bottom fishing looking for the ones that haven't moved yet. As Joe noted, there are 75 million shares outstanding. And they're broke. And more shares need to be issued to Kuhne. So many shares, that she can't do it without shareholder approval which she won't be able to get. Why would someone do a takeover when they can just buy it cheaply out of bankruptcy 7 or 8 months from now ? Dave

To: Joe Krupa who wrote (13436)	4/27/2004 2:21:02 PM
From: russet	Respond to of 14101

Could be 33.2 million different DMX shares traded in the last 4 months as some suggest, or could be a couple million trading back and forth between traders, shorters and disgruntled shareholders. I favor a scenario closer to the latter which would discount the takeover theory. The fact remains that DMX could be profitable now, if they concentrated on Pennsaid and the Solvay deal, partnered the development of other DMSO applications, jettisoned the high cost marketing and unattainable dreams of a drug empire, and spun off the WF10 albatross. They have the corporate shells to do it, and possibly/hopefully Kuhnes lawyers don't have written contracts to stop this. So at a buck, this company is a reasonable speculation as long as they stop the flow of red ink by the next GM,...and if present management and board don't, my guess is the gang will do it for them next year.